Vimarsana
Biggest News Aggregation in the World

Page 2 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal - Vimarsana News

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting...

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update - Vimarsana News

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Immunic (NASDAQ:IMUX) Downgraded to Sell at StockNews.com - Vimarsana News

Immunic (NASDAQ:IMUX) Downgraded to Sell at StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]

Source: wkrb13.com
Immunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital Management - Vimarsana News

Immunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital Management

Investment analysts at Brookline Capital Management began coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research report issued to clients and investors on Friday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. Separately, StockNews.com downgraded shares of Immunic from a “hold” rating to […]

Immunic to Host MS R&D Day and Participate in Investor Conferences in April - Vimarsana News

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...